This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print this page

In the Face of Uncertainty

A challenging future for biopharmaceutical innovation


The biopharmaceutical industry is in a precarious position regarding innovation: big bets in bold new areas are fraught with complexity and uncertainty, while success in mature therapeutic areas is becoming increasingly challenging. Sustaining innovation has consistently been difficult, but the resulting benefit to patients has generally provided innovators with an ROI sufficient enough to compensate for the risk. The balance of this equation is shifting and appears to be getting even tougher for innovators and investors. 

A recent Deloitte study has shown that the overall rate of return on R&D investment for the 12 largest biopharmaceutical firms has dropped significantly since 2010, and the cost of developing a new medicine has risen substantially. Learn more about this shift and the challenges that lie ahead for biopharmaceutical innovation.

Download the above PDF to learn more.

As used in this document, “Deloitte” means Deloitte Consulting LLP a subsidiary of Deloitte LLP. Please see for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Related links

Share this page

Email this Send to LinkedIn Send to Facebook Tweet this More sharing options

Stay connected